Altimmune (ALT) News Today $4.20 -0.06 (-1.29%) As of 09:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALTJuly 14 at 10:00 AM | globenewswire.comAltimmune Inc. Research & Ratings | ALT | Barron'sJuly 12 at 7:22 PM | barrons.comAltimmune (NASDAQ:ALT) Rating Increased to Strong Sell at The Goldman Sachs GroupJuly 12 at 3:11 AM | americanbankingnews.comAltimmune Stock Price, Quotes and Forecasts | NASDAQ:ALT - BenzingaJuly 11, 2025 | benzinga.comAltimmune’s RESTORE TRIAL: A Promising Step in ALD TreatmentJuly 11, 2025 | tipranks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. ...July 10, 2025 | gurufocus.comAltimmune (NASDAQ:ALT) Now Covered by The Goldman Sachs GroupJuly 10, 2025 | marketbeat.comJMP Securities Lowers Altimmune (NASDAQ:ALT) Price Target to $15.00July 10, 2025 | marketbeat.comAltimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)July 9, 2025 | globenewswire.comAltimmune (ALT) Reports Positive Phase 2b Results for Pemvidutide in MASH TrialJuly 9, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALTJuly 7, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALTJuly 3, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALTJuly 2, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALTJuly 1, 2025 | globenewswire.comAltimmune, Inc. (NASDAQ:ALT) Receives Average Rating of "Buy" from BrokeragesJuly 1, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALTJune 27, 2025 | prnewswire.comAltimmune's Fatty Liver Candidate Faces Differentiation DoubtsJune 27, 2025 | benzinga.comAltimmune (NASDAQ:ALT) Receives "Buy" Rating from HC WainwrightJune 27, 2025 | marketbeat.comAltimmune (NASDAQ:ALT) Hits New 12-Month Low - Here's What HappenedJune 27, 2025 | marketbeat.comAltimmune: Deciphering The MASH Crash (Rating Upgrade)June 26, 2025 | seekingalpha.comAltimmune: FDA Path Forward Remains Despite Mixed MASH Treatment Data Of PemvidutideJune 26, 2025 | seekingalpha.comAltimmune Shares Plummet After Failure to Achieve a Primary Endpoint in Phase 2b TrialJune 26, 2025 | marketwatch.comAltimmune’s stock plummets over 60% as liver drug falls short in trialJune 26, 2025 | msn.comAltimmune shares slump as weight-loss drug's fatty liver trial data disappointsJune 26, 2025 | msn.comINVESTOR ALERT: Investigation of Altimmune, Inc. (ALT) Announced by Holzer & Holzer, LLCJune 26, 2025 | globenewswire.comAltimmune shares plunge as MASH drug trial misses key fibrosis endpointJune 26, 2025 | proactiveinvestors.comAltimmune stock falls after MASH treatment trial resultsJune 26, 2025 | uk.investing.comAltimmune Shares Rise on Liver Disease Trial Data PresentationJune 26, 2025 | marketwatch.comAltimmune plunges after mid-stage trial data for MASH therapyJune 26, 2025 | msn.comAltimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionJune 26, 2025 | benzinga.comAltimmune's weight-loss drug meets main goal in fatty liver disease trialJune 26, 2025 | reuters.comAltimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASHJune 26, 2025 | globenewswire.comAltimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26June 25, 2025 | globenewswire.comALT | Altimmune Inc. Annual Cash Flow Statement - MarketWatchJune 24, 2025 | marketwatch.comAltimmune (NASDAQ:ALT) Trading Up 6.3% - What's Next?June 20, 2025 | marketbeat.comMissed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.June 18, 2025 | msn.comAltimmune (NASDAQ:ALT) Rating Lowered to Sell at Wall Street ZenJune 14, 2025 | marketbeat.comAltimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific SessionsJune 13, 2025 | finance.yahoo.comAltimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific SessionsJune 13, 2025 | globenewswire.comAltimmune (NASDAQ:ALT) Trading 8.7% Higher - Still a Buy?June 10, 2025 | marketbeat.comSquarepoint Ops LLC Cuts Stock Position in Altimmune, Inc. (NASDAQ:ALT)June 10, 2025 | marketbeat.comAltimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of "Buy" by BrokeragesJune 6, 2025 | marketbeat.comFY2026 Earnings Forecast for Altimmune Issued By B. RileyJune 5, 2025 | marketbeat.comRFG Advisory LLC Makes New Investment in Altimmune, Inc. (NASDAQ:ALT)June 5, 2025 | marketbeat.comAltimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover PotentialJune 2, 2025 | seekingalpha.comAltimmune, Inc. (NASDAQ:ALT) Stock Holdings Increased by Millennium Management LLCJune 1, 2025 | marketbeat.comTwo Sigma Investments LP Raises Holdings in Altimmune, Inc. (NASDAQ:ALT)May 30, 2025 | marketbeat.comFY2029 EPS Estimate for Altimmune Decreased by AnalystMay 27, 2025 | marketbeat.comAltimmune (NASDAQ:ALT) Upgraded to Hold at StockNews.comMay 24, 2025 | marketbeat.com13 Best Multibagger Stocks to Invest in NowMay 21, 2025 | insidermonkey.com Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address ALT Media Mentions By Week ALT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALT News Sentiment▼0.720.99▲Average Medical News Sentiment ALT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALT Articles This Week▼136▲ALT Articles Average Week Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Janux Therapeutics News Biohaven News ANI Pharmaceuticals News Mesoblast News Edgewise Therapeutics News Travere Therapeutics News CureVac News Phibro Animal Health News AbCellera Biologics News Calliditas Therapeutics AB (publ) News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALT) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
